Table 1.
Inclusion criteria | Rodondi et al. [17] (11) | Haentjens et al. [18] (12) | Ochs et al. [19] (13) | Razvi et al. [5] (14) | Singh et al. [21] (15) | Rodondi et al. [22] (16) | Gencer et al. [23] (17) | Ning etal. [11] (9) | Sun et al. [24] (18) | Moon et al. [25] (19) | Du Puy et al. [28] (25) |
---|---|---|---|---|---|---|---|---|---|---|---|
N. of included studies | 14 | 9 | 12 | 15 | 6 | 11 | 6 | 37 | 16 | 35 | 4 |
N. of analyzed patients | 13,011 | 14,912 | 14,449 | 29,022 | 14,386 | 55,287 | 25,390 | 1,473,648 | 71,808 | 555,530 | 2,116 |
Age mean/range (years) | 18–95 | – | 18–95 | 60 | 17–89 | 19–94 | 21–100 | 45–83 | 45.4–85 | 41–83.4 | 80–109 |
Follow Up mean/range (years) | – | 2–20 | 2–20 | 4–20 | 4–20 | 2.5–20 | 2–16.3 | 2.5–20 | 3.2–20 | – | 5 |
TSH cut off mU/L Subclinical hypothyroidism |
2.8–6.0 | 4–5.10 | 4–6 | 3.7–8.9 | 4–5 | 0.50 | 4.5–19.9 | 3.1–6.0 | 4–6 | – | 4.8 |
Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | Yes | No | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Unadjusted risk | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
Adjusted risk | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
Age stratified risk | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
TSH stratified risk | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
CV events analyzed | ||||||||||||||||||||||
MACE | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
Coronary events | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
Atrial fibrillation | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
Heart failure | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
CV mortality | X | X | X | X | X | X | X | X | X | X | X | |||||||||||
Overall mortality | X | X | X | X | X | X | X | X | X | X | X |